John Proudfoot, Ph. D.
30 years of experience in the pharmaceutical industry.
Leadership roles medicinal chemistry, lead identification and new concept development.
Track record of productive collaboration across disciplines to achieve project milestones.
Colleagues know me as an innovative, creative scientist who can be trusted to work collaboratively in developing practical approaches to lead generation for novel targets or concepts. I have deep experience in all aspects of medicinal chemistry particularly around lead identification by high throughput and fragment-based screening, rational design, and structure-property optimization.
Consulting for early stage companies and concepts under Flagship Pioneering, Medicxi & CMD including (among others):
Kintai Thetapeutics (2017 - present)
Janpix Limited (2017 - present)
American MedChem (, 2016-2018)
Medicinal chemistry, drug design and multiparameter optimization using in particular Knime & Stardrop as core technologies.
To December 2016:
Director, Medicinal Chemistry, Boehinger Ingelheim Pharmaceuticals, Ridgefield.
Led a group responsible for early milestone delivery in the NCE portfolio
Delivered tool and lead compounds across many target types.
Key role in the implementation of fragment-based lead identification at BI in Ridgefield.
Co-inventor of nevirapine, the first non-nucleoside HIV-1 reverse transcriptase inhibitor approved for the treatment of AIDS.
Medicinal Chemistry and Drug Design
All aspects of lead identification and progression
Analysis of hitsets, frequent hitters, cluster analysis
Evolution of hits from fragment based screening
Analog-based drug design
Structure based design
Data processing, visualization and analysis
Pipeline Pilot, Spotfire, Cytoscape, MOE, D360
Patent analysis and generation of novel intellectual property
New technology assessment and integration
US controlled substances legislation
Productive and effective cross-discipline and international interactions.
> 50 peer reviewed publications, 33 issued US patents, numerous scientific presentations.
Section editor “Successful Drug Discovery” Fischer, 2017.
Section editor “The Practice of Medicinal Chemistry” 3rd edition, Wermuth, 2008.
F1000 Faculty of Biology contributor (2007-2012)
Team member Pistoia Alliance project on Controlled Substances (2013-4)
American Chemical Society, Medicinal Chemistry Division.
American Association for the Advancement of Science
IUPAC, subcommittee on Medicinal Chemistry and Drug Development
New York Academy of Sciences